Molecular marker related to oral squamous cell carcinoma metastasis and application thereof

By discovering PLIN2 as a molecular marker related to OSCC transfer, it provides a method to detect and intervene OSCC transfer, which solves the shortcomings of metastasis judgment in early diagnosis and treatment of OSCC in the prior art, and realizes early prediction and intervention of OSCC transfer, improving The targeted and effective treatment.

CN118957077APending Publication Date: 2024-11-15HOSPITAL OF STOMATOLOGY SUN YAT SEN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411323281.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-23
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The prior art is difficult to effectively judge tumor metastasis in the early diagnosis and treatment of oral squamous cell carcinoma (OSCC). In particular, the lipid metabolism index PLIN2 has not been studied for the judgment of OSCC metastasis and prognosis, resulting in large side effects and insignificant effects of treatment. The problem.

Method used

By discovering and verifying that PLIN2 is a molecular marker, its high expression is related to OSCC metastasis and prognosis, it provides a kit for detecting PLIN2 gene expression level or protein content for early diagnosis and prognosis judgment, and uses Si-RNA transfection technology to knock out Low PLIN2 expression to inhibit the migration and invasion ability of OSCC cells, and prepare drugs for intervention in OSCC metastasis.

Benefits of technology

Effectively predicting whether OSCC is metastatic, providing molecular means to early diagnosis and intervention of OSCC metastasis, and interfering with OSCC metastasis by changing the expression level of PLIN2 molecules, improving the targetedness and effectiveness of treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118957077A_ABST
    Figure CN118957077A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biological medicine, in particular to a molecular marker related to oral squamous cell carcinoma metastasis and application of the molecular marker. The molecular marker related to the metastasis of the oral squamous cell carcinoma is perilipid droplet protein PLIN2. The research finds that PLIN2 is remarkably and highly expressed in a lymph node metastasis group of an OSCC patient; in addition, the overall lifetime of an OSCC patient with high PLIN2 expression is remarkably shortened; the result shows that the high expression of the PLIN2 is related to the OSCC metastasis and prognosis, and prompts that the PLIN2 can be used as a marker for preparing a product for early diagnosis of the OSCC metastasis or prognosis, and may become a target for early intervention of the OSCC metastasis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and in particular to a molecular marker associated with oral squamous cell carcinoma metastasis and an application thereof. Background Art

[0002] Oral squamous cell carcinoma (OSCC) is an invasive epithelial tumor, accounting for about 90% of oral malignancies, with a 5-year survival rate of about 60%. Among all the causes of death, tumor metastasis occupies the primary position, and its occurrence and development can be regulated by a variety of factors. Tobacco, alcohol, HPV infection and other internal and external factors are well-known risk factors for OSCC progression. With the increasing proportion of obese people worldwide, obesity and the lipid metabolism abnormalities it causes are also considered to be one of the important risk factors for tumor metastasis. Therefore, a comprehensive understanding of the mechanism of lipid metabolism in the progression of OSCC and the search for metabolic molecular markers of OSCC metastasis are of great significance for the early diagnosis and prevention of disease metastasis.

[0003] At present, the methods for judging OSCC metastasis mainly include the use of pathological sections, imaging techniques and other methods to detect whether there is OSCC cell infiltration in the periphery of the tumor, lymph nodes, lungs and other distant tissues. However, these methods for judging tumor metastasis are only applicable to the late stage of the tumor and fail to make advance assessments before the tumor metastasizes. In addition, conventional treatments for OSCC metastasis include radiotherapy, chemotherapy, immunotherapy, etc., but they have disadvantages such as large side effects and insignificant effects. In recent years, the detection of biomarkers can make early diagnosis of the prognosis and development of the disease, and targeted therapy at the relevant cellular and molecular levels is becoming a new treatment model.

[0004] Perilipin 2 (PLIN2) is the main structural protein on the surface of lipid droplets. In recent years, it has been found that it is not only involved in lipid storage, but also associated with a variety of metabolic diseases and tumors. Currently, there are limited means for early diagnosis and treatment of OSCC metastasis, especially the lipid metabolism indicator PLIN2 has not been studied for the judgment of OSCC metastasis and prognosis. Summary of the invention

[0005] The purpose of the present invention is to overcome the shortcomings of the prior art and provide a molecular marker related to oral squamous cell carcinoma metastasis, namely PLIN2. The high expression of PLIN2 is related to OSCC metastasis and prognosis.

[0006] To achieve the above object, the technical solution adopted by the present invention is:

[0007] In a first aspect, the present invention provides a molecular marker associated with oral squamous cell carcinoma metastasis, wherein the molecular marker comprises PLIN2.

[0008] The present invention uses a variety of technical methods such as patient clinical specimens, in vitro cell culture, and in vivo animal experiments to confirm the relationship between PLIN2 and OSCC metastasis. It is found that in patient samples with lymph node metastasis, the expression level of PLIN2 is significantly higher than that of patient samples without lymph node metastasis, and is associated with a reduced patient survival. Upregulation of PLIN2 protein expression can significantly promote the invasion and migration of OSCC cells. Therefore, by detecting the PLIN2 gene expression level or protein content in the sample, it is possible to effectively predict whether oral squamous cell carcinoma has metastasis.

[0009] Preferably, the PLIN2 is highly expressed in patient samples of oral squamous cell carcinoma metastasis.

[0010] Preferably, the patient sample is a tissue section sample.

[0011] In a second aspect, the present invention provides the use of a reagent for detecting the expression level of the molecular marker gene and / or protein in the preparation of a product for early diagnosis of oral squamous cell carcinoma metastasis or prognosis.

[0012] Preferably, the oral squamous cell carcinoma metastasis comprises oral squamous cell carcinoma lymph node metastasis.

[0013] In a third aspect, the present invention provides a kit for early diagnosis of oral squamous cell carcinoma metastasis or prognosis, the kit comprising a reagent for detecting the expression level of the molecular marker gene and / or protein.

[0014] Preferably, the kit comprises primers whose nucleotide sequences are shown as SEQ ID NO.1 and SEQ ID NO.2.

[0015] In a fourth aspect, the present invention provides the use of PLIN2 as a target in screening or preparing a drug for early intervention of oral squamous cell carcinoma metastasis.

[0016] In a fifth aspect, the present invention provides the use of a preparation for inhibiting the expression level of PLIN2 gene and / or protein in the preparation of a drug for treating metastasis of oral squamous cell carcinoma.

[0017] The present invention uses Si-RNA transfection technology to knock down the expression of PLIN2 in the OSCC cell line HSC6, and the results show that the migration and invasion abilities of cells in vitro culture are significantly reduced. After knocking down PLIN2 in the OSCC cell line, the expression levels of EMT-related indicators are downregulated.

[0018] Preferably, the agent for inhibiting the expression level of PLIN2 gene and / or protein comprises Si-RNA targeting and knocking down PLIN2.

[0019] Preferably, the nucleotide sequence of the Si-RNA is shown as SEQ ID NO.3 or SEQ ID NO.4.

[0020] In a sixth aspect, the present invention provides a drug for treating oral squamous cell carcinoma metastasis, the drug comprising a preparation that inhibits the expression level of PLIN2 gene and / or protein.

[0021] The beneficial effects of the present invention are:

[0022] The present invention uses a variety of technical methods such as patient clinical specimens, in vitro cell culture, and in vivo animal experiments to confirm the relationship between PLIN2 and OSCC metastasis. It is found that in patient samples with lymph node metastasis, the expression level of PLIN2 is significantly higher than that of patient samples without lymph node metastasis, and is associated with a reduced patient survival. Upregulation of PLIN2 protein expression can significantly promote the invasion and migration of OSCC cells. Therefore, by detecting the PLIN2 gene expression level or protein content in the sample, it is possible to effectively predict whether oral squamous cell carcinoma has metastasis; PLIN2 may become a therapeutic target for intervening in OSCC metastasis.

[0023] The present invention discovered for the first time that the lipid metabolism molecular marker PLIN2 is associated with OSCC metastasis, and PLIN2 can be used as a marker for preparing products for early diagnosis of OSCC metastasis and prognosis.

[0024] The present invention provides a molecular means for early intervention of oral squamous cell carcinoma metastasis, which intervenes in or inhibits the metastasis of OSCC by changing the expression level of PLIN2 molecules in OSCC. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 Figure 2 shows the expression of PLIN2 gene in OSCC patient specimens and its relationship with patient survival prognosis; Figure A shows the expression of PLIN2 in OSCC patients analyzed using the TCGA database, Figure B shows the relationship between PLIN2 gene and patient survival prognosis analyzed using the TCGA database, Figure C shows the expression of PLIN2 in OSCC patients analyzed using the GSE65858 dataset, and Figure D shows the relationship between PLIN2 gene and patient survival prognosis analyzed using the GSE65858 dataset.

[0026] Figure 2 The efficiency of siRNA knockdown of PLIN2 was detected by qRT-PCR and Western Blot; Figure A is the result of qRT-PCR detection; Figure B is the result of Western Blot detection.

[0027] Figure 3Transwell chamber was used to detect the effect of PLIN2 knockdown on OSCC cell migration and invasion; Figure A shows the microscopic observation results of migrating cells and the statistical results of cell number comparison among groups; Figure B shows the microscopic observation results of invasive cells and the statistical results of cell number comparison among groups.

[0028] Figure 4 qRT-PCR and Western Blot were used to detect the stable overexpression of PLIN2 by lentivirus; Figure A is the result of qRT-PCR detection; Figure B is the result of Western Blot detection.

[0029] Figure 5 Transwell chamber was used to detect the effect of PLIN2 overexpression on OSCC cell migration and invasion; Figure A shows the microscopic observation results of migrating cells and the statistical results of cell number comparison among groups; Figure B shows the microscopic observation results of invasive cells and the statistical results of cell number comparison among groups.

[0030] Figure 6 qRT-PCR and Western Blot were used to detect epithelial-mesenchymal transition indicators in OSCC cells after PLIN2 knockdown or overexpression; Figure A shows the results of epithelial-mesenchymal transition indicator detection in OSCC cells after PLIN2 overexpression; Figure B shows the results of epithelial-mesenchymal transition indicator detection in OSCC cells after PLIN2 knockdown.

[0031] Figure 7 To observe the effect of PLIN2 overexpression on the in vivo metastasis of OSCC cells through the nude mouse tail vein metastasis model; Figure A is the imaging of the cells in the mouse after the nude mouse tail vein was injected with OSCC cells overexpressing PLIN2, Figure B is the pathological tissue staining of lung tumor metastasis, and Figure C is a statistical chart of lung metastasis. DETAILED DESCRIPTION

[0032] In order to better illustrate the purpose, technical solutions and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments.

[0033] The primers and their sequences used in the present invention are shown in Table 1 and were synthesized by Shanghai Jierui Biotechnology Co., Ltd.

[0034] Table 1

[0035] Primers Sequence (5'-3') PLIN2-F TTGCAGTTGCCAATACCTATGC PLIN2-R CCAGTCACAGTAGTCGTCACA SNAI1-F CAGACCCACTCAGATGTCAAG SNAI1-R CTTGTGGAGCAGGGACATT GAPDH-F CTCCTCCTGTTCGACAGTCAGC GAPDH-R CCCAATACGACCAAATCCGTT CDH1-F CTCCACAGCCACCGTCACC CDH1-R GCCCACGCCAAAGTCCTCG CDH2-F CTTCATTATCAACCCCATCTCG CDH2-R CTCAAATGAAACCGGGCTA VIM-F GATGTTTCCAAGCCTGACCT VIM-R GTACCATTCTTCTGCCTCCTG

[0036] Example 1: Analysis of the expression of PLIN2 in OSCC and its relationship with prognosis

[0037] Gene expression data and corresponding clinical information of OSCC patients were obtained from the Cancer Genome Atlas (TCGA) database (https: / / portal.gdc.cancer.gov / ) and the high-throughput gene expression Omnibus (GEO) database. The TCGA dataset contains 321 OSCC patients, and the GSE65858 dataset (https: / / www.ncbi.nlm.nih.gov / geo / geo2r / ?acc=GSE65858) contains 267 OSCC patients.

[0038] First, according to the clinical information of the patients, OSCC patients in the TCGA and GSE65858 datasets were divided into metastatic group and non-metastatic group according to whether lymph node metastasis occurred, and then the difference in PLIN2 expression between the two groups was compared. The R package "survminer" was used to analyze and determine the optimal cutoff value of PLIN2 expression, so that the patients were divided into high expression group and low expression group (among which, the cutoff value of TCGA database calculated and analyzed by R package was 5.3, high expression group N=76, low expression group N=245; the cutoff value of GSE65858 database calculated and analyzed by R package was 8.39, high expression group N=150, low expression group N=117). Combined with the clinical information of the patients, the Kaplan-Meier method was used to draw the survival curve and the log-rank test was used to compare the differences between the groups, analyze the effect of PLIN2 expression on the survival time of patients and analyze its role in suggesting the prognosis of patients.

[0039] The results of TCGA database analysis showed that PLIN2 was significantly overexpressed in OSCC patients with lymph node metastasis, P<0.05( Figure 1 A); In addition, the overall survival of OSCC patients with high PLIN2 expression was significantly lower than that of patients with low PLIN2 expression, P<0.05 ( Figure 1 B). The analysis results of GSE65858 dataset are consistent with those of TCGA database ( Figure 1 C, D), indicating that PLIN2 is highly expressed in specimens of OSCC patients with lymph node metastasis, and its high expression is associated with poor prognosis of patients; OSCC patients with high expression of PLIN2 have a significantly shortened overall survival.

[0040] Example 2: Knockdown of PLIN2 expression using Si-RNA transfection technology

[0041] In order to explore the effect of low expression of PLIN2 on the migration and invasion of OSCC cells, this example constructed an OSCC cell line with transient knockdown of PLIN2 by Si-RNA to explore its effect on cell phenotype.

[0042] 1. OSCC cell line - HSC6 cell culture

[0043] (1.1) Cell culture conditions: The culture medium was DMEM high-glucose medium containing a mixture of 10% fetal bovine serum and 1% penicillin-streptomycin. All cells were cultured in a 37°C cell culture incubator containing 5% CO2.

[0044] (1.2) Cell recovery: Take out the cells to be recovered from the liquid nitrogen tank, transfer them to a -80℃ refrigerator and let them stand. After the liquid nitrogen evaporates, take them out immediately and place them in a 37℃ constant temperature water bath for rapid thawing. After thawing, quickly transfer them to a 15mL centrifuge tube containing 4mL of complete culture medium and centrifuge them at 1000rpm for 5min. After centrifugation, gently discard the supernatant, pipet the cells in the centrifuge tube with 2mL of complete culture medium, transfer the cell resuspension to a 6cm cell culture dish containing 3mL of complete culture medium and shake gently to mix, and place them in a cell culture incubator. After the cells adhere to the wall, replace the culture medium with fresh one or perform cell passage within 24h according to the degree of cell confluence.

[0045] (1.3) Cell passaging and cryopreservation: When the cell confluence reaches 80-90%, remove the original cell culture medium, gently rinse the cell culture dish 2-3 times with sterile phosphate buffered saline (PBS), add 0.25% trypsin, and place in a cell culture incubator for digestion for 3 minutes. After taking out, gently tap the side wall of the culture dish and observe under a microscope. If most of the cells become round and float, add 3 times the volume of trypsin to stop digestion. Transfer the cell suspension in the culture dish to a 15ml centrifuge tube, centrifuge at 1000rpm for 5 minutes, and gently discard the supernatant. Passage at a ratio of 1:2-1:3, observe the cells every day, replace fresh culture medium or pass the cells according to the cell confluence. The newly revived cells need to be passaged 2-3 times, and the next experimental treatment can be carried out after the cell characteristics are stable. If cells are to be frozen, calculate the required volume of freezing solution according to the amount of cell resuspension that can be added to each cryotube, prepare it in advance according to the volume ratio of DMSO:FBS=1:9, and centrifuge at 1000rpm for 5 minutes, discard the supernatant, add the corresponding volume of freezing solution to the centrifuge tube, pipet and mix well, and transfer to the cryotube that has been carefully labeled. Place the cryotube in a gradient freezing box and store it in a -80℃ refrigerator for a short term. Transfer it to liquid nitrogen for long-term storage.

[0046] 2. Construction of knockdown cell lines by small interfering RNA (Si-RNA) transfection

[0047] The Si-RNA sequence for targeted knockdown of PLIN2 and the negative control Si-RNA sequence (Si-NC, catalog number: siN0000001) were both commissioned to Guangzhou Ruibo Biotechnology Co., Ltd. for synthesis. The sequence of Si-PLIN2-1 is (GACTGCCTATTCTGAATCA) and the sequence of Si-PLIN2-2 is (GTCACGTACTCTTGCAATT). HSC6 cells in the logarithmic phase were digested, inoculated into 6-well plates, and incubated overnight in an incubator. When the degree of confluence reached 60-80%, a transfection reagent was prepared in a sterile enzyme-free EP tube using a sterile enzyme-free pipette tip, wherein liquid A was 5 μL siRNA + 120 μL Opti-MEM culture medium, and liquid B was 5 μL RNAiMAX (transfection reagent) + 120 μL Opti-MEM culture medium; liquid A and liquid B were mixed and incubated at room temperature for 3 minutes, then liquid B was added to liquid A, gently mixed and incubated at room temperature for 5 minutes; while mixing and incubating, the six-well plate was taken out of the incubator and the original culture medium was removed, and after rinsing with PBS buffer twice, A and B were evenly added dropwise to each well to obtain a total of 250 μL of the mixed solution, at which time the final content of siRNA in each well was 100 pmol, and 500 μL was added to each well. Opti-MEM culture medium, mix the six-well plate in an "8" shape and return it to the cell culture incubator for 6-12 hours. After rinsing with PBS buffer, add 2 mL of complete culture medium to each well. Continue to incubate in the cell culture incubator for 1-4 days. During this period, verify the knockdown efficiency of PLIN2 by qRT-PCR and WB, and carry out subsequent functional experiments.

[0048] 3. Detect the efficiency of PLIN2 knockdown by qRT-PCR (real-time quantitative polymerase chain reaction, Real time quantitative PCR)

[0049] The specific experimental methods are as follows:

[0050] (1) RNA extraction: Take out the six-well plate from the cell culture incubator, remove the original culture medium, rinse with PBS buffer three times, and then aspirate all the remaining rinse solution. Then use the RNA rapid extraction kit to extract RNA. Be careful to keep the operation without enzymes throughout the process. First, add 500μL Lysis Buffer to each well, rub the top of the enzyme-free pipette tip on the bottom of the dish to make the lysis solution fully contact with the cells, then add 500μL enzyme-free anhydrous ethanol to each well, blow and mix with the pipette tip, then transfer the liquid in the well to an enzyme-free ep tube, oscillate on a vortex oscillator for 10s, then blow and mix with the pipette tip, and transfer the mixed liquid to the centrifuge column, centrifuge at 12000g for 1min at room temperature, remove the centrifuge column from the tube after centrifugation, pour out the waste liquid in the tube and put the centrifuge column back, add 500μL Wash Buffer, centrifuge at 12000g for 1min at room temperature, pour out the waste liquid in the tube and put it back into the centrifuge column again, centrifuge the empty tube at 12000g for 1min at room temperature, put the centrifuge column in a clean enzyme-free ep tube, open the lid and dry it for 2min, then add 20-40μL Elution to the center of the membrane of the centrifuge column Buffer, stand at room temperature for 2 minutes, centrifuge at 12000g for 1 minute, add the RNA solution eluted after centrifugation back to the column, stand on ice for 5 minutes, and centrifuge again at 12000g for 1 minute to improve the RNA elution efficiency. After discarding the centrifuge column, place the RNA on ice and use the micro-spectrophotometer Nano-Drop2000 to measure the OD value of the RNA. If the A260 / 280 ratio is between 1.9-2.2, record the RNA concentration and calculate the volume corresponding to 1μg RNA. It can be used directly in subsequent experiments or temporarily stored in a -80℃ refrigerator.

[0051] (2) RNA reverse transcription: The entire reverse transcription process should be performed on ice. First, add each component according to Table 2 to a 200 μL enzyme-free ep tube, centrifuge briefly, and heat at 42°C for 2 min in a PCR instrument to remove genomic DNA.

[0052] Table 2

[0053] Components Addition amount Total RNA Volume for 1 μg of total RNA 4×gDNA wiper Mix 4μL Enzyme-free water Make up to 16 μL

[0054] Then add 4 μL of 5×Hiscript II qRT SuperMix II directly to the reaction tube in the first step, mix by gently pipetting, heat at 50°C for 15 min after centrifugation, and then heat at 85°C for 5 s. After termination at 4°C, the reverse transcription is complete. Dilute the cDNA obtained by reverse transcription 3 times with enzyme-free water. It can be used directly in subsequent experiments or temporarily stored in a -20°C refrigerator.

[0055] (3) qRT-PCR detection: PCR primers GAPDH-F, GAPDH-R, PLIN2-F, and PLIN2-R were designed in advance and submitted to Shanghai Jierui Biotechnology Co., Ltd. for synthesis. The dry powder primers were prepared into a 100 μmol mother liquor with enzyme-free water, and a portion was taken out and diluted to a working concentration of 10 μmol and stored in a -20°C refrigerator.

[0056] First, add each component (20 μL in total) according to Table 3 to a 200 μL enzyme-free ep tube, mix well with a pipette tip and centrifuge briefly.

[0057] Table 3

[0058]

[0059] After mixing, set the PCR conditions shown in Table 4 below for reaction:

[0060] Table 4

[0061]

[0062] After the reaction, the ΔCT value corresponding to each well was recorded, and the ΔCT values ​​corresponding to the three duplicate wells of the same sample were averaged to be regarded as the ΔCT value of the sample; the ΔCT value of the target gene was subtracted from the ΔCT value of the corresponding internal reference gene to calculate 2 -ΔΔCT The relative expression level of the target gene mRNA was obtained.

[0063] 4. The efficiency of PLIN2 knockdown was detected by Western blot (WB). The specific experimental method is as follows:

[0064] (1) Protein extraction: Take out the six-well plate to be extracted from the cell culture incubator, remove the original culture medium, rinse three times with 4℃ precooled PBS buffer, aspirate all the residual rinse solution and place the six-well plate on ice. The whole process should be carried out on ice. Calculate the total volume of lysis solution required (60μL / well) and prepare it according to the ratio of RIPA: phosphatase inhibitor: protease inhibitor = 98:1:1. Add lysis solution evenly to the wells and place them on a shaker at 4℃ for 30min. During the lysis process, scrape the cells clean and dry them in an oven, then precool them at 4℃, and precool the centrifuge to 4℃. After the lysis is completed, scrape the cells to the bottom with a clean cell scraper, transfer the cell fragments and lysis solution to a 1.5mL ep tube with a pipette, centrifuge at 14000g for 30min at 4℃, aspirate the supernatant after centrifugation and transfer it to a 600μL ep tube. You can continue to carry out subsequent experiments or store it in a -80℃ refrigerator.

[0065] (2) Determination of protein concentration by BCA method: First, the BSA standard was diluted with PBS buffer precooled at 4°C to obtain BSA standard dilution solutions with final concentrations of 2, 1, 0.5, 0.25, 0.125, and 0.0625 μg / μL, respectively; at the same time, the total amount of BCA working solution required (200 μL / well) was calculated, and the BCA working solution was prepared according to the ratio of BCA-A:BCA-B=50:1 and mixed thoroughly. Then, the diluted BSA standard was added to the 96-well plate from top to bottom according to the concentration gradient at a volume of 25 μL / well, and 25 μL of PBS buffer used to dilute the BSA standard was added to the 7th well. Two columns of parallel controls were set for the standard; the protein sample to be tested was added to the 96-well plate at a volume of 2.5 μL / well and 22.5 μL of PBS buffer was added to ensure that the total volume of each well was 25 μL, and 3 duplicate wells were set for each protein sample. Finally, add 200 μL of BCA working solution to each well, mix thoroughly, cover the 96-well plate, incubate at 37°C for 30 minutes, and use a full-wavelength microplate reader to detect the absorbance value (OD value) of each well at a wavelength of 562 nm within 3-5 minutes and record it. Draw a standard curve based on the absorbance readings of the standard after removing the background value, and calculate the actual concentration and the sample volume corresponding to 30 μg of the protein to be tested based on the absorbance value of the protein sample to be tested.

[0066] (3) Protein denaturation: After determining the protein concentration, add 5X SDS-PAGE loading buffer (4:1) containing bromophenol blue indicator to the protein, then heat at 99°C for 10 min. After heating, place on ice and spin off immediately after cooling to ensure that the water vapor on the tube wall is mixed at the bottom to avoid concentration changes. You can continue with subsequent experiments or store in a -20°C refrigerator.

[0067] (4) SDS-PAGE electrophoresis: First, prepare 10% separation gel and 5% stacking gel according to the instructions of the gel preparation kit. While waiting for the gel to be prepared, prepare the electrophoresis solution and transfer solution. After fully mixing, place the transfer solution in a 4°C refrigerator for later use. After the stacking gel solidifies, install the gel device in the electrophoresis tank, pour the electrophoresis solution so that it exceeds the top of the loading well, and then gently remove the comb teeth in parallel in the electrophoresis solution. According to the pre-designed loading order, add the corresponding volume of target protein sample and different volumes of protein molecular weight marker to each well. After connecting the electrodes of the electrophoresis tank, first perform electrophoresis at a constant voltage of 50V for 30 minutes to ensure that the protein is flattened into a straight line in the stacking gel, and then perform electrophoresis at a constant voltage of 100-110V for 60 minutes. Continue to observe until the green marker is close to the bottom of the gel and stop the electrophoresis.

[0068] (5) Transfer: Cut the PVDF membrane to 8.5×5.5 cm in advance and soak it in methanol solution for 1 min before transfer, then soak it in transfer solution for later use. After the electrophoresis is completed, gently pry open the glass plate with a pick, cut off the excess concentrated gel at the upper edge, and gently insert the pick parallel to the gel and the glass plate in the transfer solution to loosen the gel. Place the bottom of the glass plate against the edge of the iron box, lift the glass plate and the gel horizontally, buckle three layers of filter paper and a layer of sponge on the gel, flip it over to transfer the gel to the filter paper, and then gently spread the PVDF membrane from one side onto the gel to ensure that no bubbles are generated. Then cover the membrane with three layers of filter paper and a layer of sponge, and then transfer it as a whole to the transfer clamp with the black side down. After clamping, put the black side to the black side into the transfer tank, pour all the transfer solution, connect the electrodes, and transfer the membrane on ice at a constant current of 200 mA for 1.5-2 hours (the specific time depends on the molecular weight of the target protein).

[0069] (6) Blocking: After the transfer begins, use TBST to prepare a 5% skim milk powder solution. After the transfer is completed, place the membrane with the front side facing up (i.e., the cut corner ends on the upper right side) and gently wash it in TBST. Then, immerse it with the front side facing up in a 5% skim milk powder solution and place it on a shaker at room temperature for 1 hour to block.

[0070] (7) Primary antibody incubation: Before blocking, prepare the primary antibody in advance using the primary antibody diluent according to the ratio recommended in the antibody manual (PLIN2, Novus Biologicals, 1:500; E-Cadherin, Cell Signaling Technology, 1:1000; Snail, Cell Signaling Technology, 1:1000; N-Cadherin, Proteintech, 1:2000; Vimentin, Proteintech, 1:10000; GAPDH, Proteintech, 1:20000). After blocking, place the PVDF membrane in a thin film glove, mark the target protein molecular weight and the position of the protein marker, and cut out the corresponding bands. Soak the bands in the prepared primary antibody and shake at 4°C overnight.

[0071] (8) Secondary antibody incubation: Select a secondary antibody corresponding to the species of the primary antibody and dilute the secondary antibody with the 5% skim milk powder solution recovered after blocking (Beijing Yimabo Technology Co., Ltd., 1:4000). After recovering the primary antibody, wash the membrane with TBST for 5 min × 3 times. After absorbing the residual TBST, add the corresponding secondary antibody and incubate on a shaker at room temperature for 1 h.

[0072] (9) Development: After the secondary antibody incubation, wash the membrane with TBST for 10 min × 3 times, prepare ECL luminescent solution in a 1:1 ratio, evenly cover the strips, and then expose using an ultra-high sensitivity chemiluminescence imaging system. Save the development image and perform qualitative comparison of protein expression as needed.

[0073] 5. After knocking down PLIN2 in HSC6 cells, the Transwell migration and invasion assay was used to detect changes in the in vitro migration and invasion ability of OSCC cells.

[0074] For the Transwell migration assay, PLIN2 overexpression / knockdown cells in the logarithmic growth phase were digested, terminated, centrifuged, resuspended in FBS-free medium, and counted. The number of cells required for the initial seeding of different cell lines (4 × 10 4 -3×10 5 ), transfer the corresponding volume of cell resuspension to a sterile ep tube and fill it up to 200 μL with serum-free medium; then add 800 μl of complete medium to the 24-well plate and gently place the adapted 8 μm Transwell chamber into it; finally, gently blow and mix the 200 μL cell resuspension in the sterile ep tube, add it to the top of the chamber and put the 24-well plate back into the cell culture incubator. During the whole process, care should be taken to avoid generating bubbles above or below the chamber.

[0075] For the Transwell invasion experiment, 800 μL of complete culture medium was added to the 24-well plate in advance and the adapted 8 μm Transwell chamber was gently placed in it. 50 μL of diluted Matrigel matrix gel (matrix collagen solution: serum-free culture medium = 1:9) was evenly spread on the bottom of the chamber. After standing in the cell culture incubator for 2 h, 200 μL of cell resuspension solution was added to the upper chamber. The initial cell amount required for invasion of different cell lines ranged from 6×10 4 -3×10 5 .

[0076] After the cells migrated / invaded in the incubator for 24 h, the 24-well plate was removed and gently rinsed with PBS buffer to remove the culture medium in the chamber. After fixation with 4% paraformaldehyde for 25 min, the plate was stained with 0.5% crystal violet solution for 30 min. After rinsing with PBS again, the non-migrated / invaded cells on the upper layer of the chamber filter membrane were wiped clean with a cotton swab. Under the 20x objective of a color inverted microscope, 5 fields of view were randomly selected from each chamber for photographing and recording. The number of cells that passed through the membrane in each field of view was counted and compared between groups.

[0077] The results of qRT-PCR and WB experiments confirmed that the mRNA expression level and protein expression level of PLIN2 were significantly decreased ( Figure 2A, B), indicating that the present example used Si-RNA transfection technology to effectively knock down the expression of PLIN2 in the OSCC cell line HSC6.

[0078] Transwell assay results showed that knockdown of PLIN2 could significantly inhibit the migration of OSCC cells ( Figure 3 A) and invasive ability ( Figure 3 B).

[0079] Example 3: Construction of overexpression cell lines by lentiviral infection

[0080] In order to explore the effect of PLIN2 overexpression on OSCC cell migration and invasion, this example constructed OSCC cell lines stably overexpressing PLIN2: HSC3 cell line and CAL33 cell line by using lentiviral-packaged overexpression plasmid vectors to explore their effects on cell phenotypes. The specific experimental methods are as follows:

[0081] (1) Construction of overexpression plasmid and packaging of lentivirus: The plasmid overexpressing human PLIN2 gene and the subsequent packaging of lentivirus and virus titer detection were all completed by Shanghai GeneCare Gene Medicine Technology Co., Ltd.

[0082] The specific process is as follows: the CDs region of PLIN2 was subcloned using Taq DNA polymerase and inserted into the BamHI / AgeI site of the GV260 lentiviral vector. After the sequence alignment was correct, the lentivirus was packaged and the titer of the finished virus was tested. The titer of LV-PLIN2 was 3.5×10 8 TU / mL, and the titer of the negative control virus CON101 (Ubi-MCS-firefly-Luciferase-IRES-Puromycin) was 8×10 8 TU / mL.

[0083]

[0084] (2) Determining the appropriate cell line and puromycin screening concentration: HSC3 and CAL33 cells in the logarithmic growth phase (cell culture method refers to step 1 in Example 2) were digested and inoculated into 24-well plates, with 2×10 cells per well. 4 cells and incubated them overnight in a cell culture incubator; complete culture medium (without double antibody) containing different concentrations of puromycin (puro) was prepared, and after removing the original culture medium, 2 mL of complete culture medium containing the corresponding concentration of puro was added to each well. The cell status was observed under a microscope 24 h and 48 h after the addition of puro, and the lowest puro concentration that caused all cell death at 48 h was selected as the initial screening concentration (2 μg / mL) after lentiviral infection of the cell line, and 1 / 2 of this concentration was used as the maintenance concentration (1 μg / mL) after the initial screening.

[0085] (3) Inoculation and infection of cells: Digest the cells in the logarithmic growth phase in advance, inoculate them in a six-well plate, and incubate them overnight. When the cell confluence reaches about 30-50%, remove the original culture medium, rinse with PBS buffer, and add 1 mL of complete culture medium containing 40 μL of HitransG infection enhancement solution to each well. Then, calculate the required volume of the finished virus solution based on the virus titer, cell number and appropriate multiplicity of infection (MOI), virus volume = (MOI × cell number) / virus titer (the appropriate MOI for HSC3 and CAL33 cell lines in this study is 20). Take the lentivirus out of the -80°C refrigerator in advance, dissolve it in an ice bath, add the corresponding volume of virus solution to each well, and then put the six-well plate back into the cell culture. After incubation for 4 hours, add 1 mL of 40 μL of The complete medium of HitransG infection enhancement solution was returned to the cell culture incubator for further infection. After 12-16 hours, the virus infection solution was removed, and 2 mL of complete medium was added to each well after rinsing with PBS; then the cells were cultured in a 37°C incubator, and the medium was changed according to the cell confluence. When the cell confluence reached 90%, the cells were subcultured to a 6 cm culture dish. When the confluence in the culture dish reached 70-80%, the infected cells were screened for puromycin resistance according to the pre-determined puro screening concentration. After 7-14 days of screening, the overexpression efficiency of PLIN2 was verified by qRT-PCR and WB (the experimental method refers to steps 3-4 of Example 2). After confirming that a stable overexpression cell line was established, the surviving cells were amplified, subcultured, and cryopreserved with complete medium containing the maintenance concentration of puro, and subsequent functional experiments were carried out. After HSC3 and CAL33 cells overexpressed PLIN2, the changes in the migration and invasion ability of OSCC cells in vitro were detected by Transwell assay (the experimental method refers to step 5 of Example 2).

[0086] In this example, the finished lentivirus packaged with the overexpression human PLIN2 plasmid was used to infect the HSC3 cell line and the CAL33 cell line. After the OSCC cell line stably overexpressing PLIN2 was established through puro resistance screening, the qRT-PCR and WB results confirmed that the mRNA expression level of PLIN2 was ( Figure 4 A, 4C) and protein expression levels ( Figure 4 B, 4D) significantly increased. This shows that the present invention successfully constructed HSC3 and CAL33 cells overexpressing PLIN2 by lentiviral transfection.

[0087] Transwell assay results showed that overexpression of PLIN2 could significantly enhance the migration of OSCC cells. Figure 5 A) and invasive ability ( Figure 5 B).

[0088] Example 4: Effect of PLIN2 overexpression / knockdown on EMT marker gene expression levels

[0089] EMT mainly plays a role in the initial stage of distant metastasis of tumors, and can make tumor cells lose epithelial characteristics and show mesenchymal cell characteristics, so as to obtain migration and invasion ability. Considering the important role played by EMT in cancer cell metastasis, the present embodiment detects overexpression / knockdown of PLIN2 by qRT-PCR and WB technology (experimental method reference embodiment 2 step 3-4), and the changes of EMT-related markers in OSCC cells at the transcription level and protein level, and the influence of expression level. The EMT-related markers include: epithelial cell marker E-cadherin (E-cadherin, encoding gene CDH1), mesenchymal cell marker N-cadherin (N-cadherin, encoding gene CDH2), vimentin (Vimentin, encoding gene VIM), transcription factor Snail (encoding gene SNAI1). The primer sequences used in the present embodiment are referenced to Table 1.

[0090] The results showed that after overexpression of PLIN2, the expression of epithelial cell marker E-cadherin (encoded by CDH1) decreased, while the expression of mesenchymal cell markers N-cadherin (encoded by CDH2), vimentin (encoded by VIM) and transcription factor Snail (encoded by SNAI1) increased ( Figure 6 A); knocking down PLIN2 resulted in the opposite effect ( Figure 6 B).

[0091] Therefore, PLIN2 overexpression upregulates EMT indicators in OSCC cells, while PLIN2 knockdown downregulates EMT indicators in OSCC cells, suggesting that PLIN2 upregulation can promote the migration and invasion of OSCC cells by inducing EMT.

[0092] Example 5: Nude mouse tail vein transfer experiment

[0093] In this example, the effect of PLIN2 overexpression on the metastasis of OSCC cells in vivo was observed by using a nude mouse tail vein metastasis model. The specific experimental method is as follows:

[0094] HSC3 cells stably overexpressing PLIN2 and HSC3 cells infected with the negative control virus CON101 were digested, centrifuged, resuspended, and counted. Each nude mouse was injected with 1.5×10 6 The total number of cells required for each group (15 / group) was calculated based on the number of cells per nude mouse, and the total amount of serum-free culture medium required for each group was calculated based on the injection of 200 μL of cell suspension into each nude mouse. The total number of cells required for each group was then taken, re-centrifuged, resuspended in the corresponding volume of serum-free culture medium, pipetted and mixed, and then dispensed into 1.5 mL sterile EP tubes, placed on ice and transported to the animal experiment center.

[0095] The mouse holder is stably adsorbed on the ultra-clean operating table. The distance from the edge of the table is such that the middle finger can stably touch the side edge of the table after the nude mouse tail is tightened by the thumb and index finger. The nude mouse is placed in the holder, with its nose facing the front air outlet. The degree of fixation is such that the nude mouse cannot turn its head in it. The nude mouse tail is straightened, and the nude mouse tail is repeatedly wiped with an alcohol cotton ball to see the position of the tail vein clearly. 200 μL of mixed serum-free cell resuspension is drawn in advance with a 1mL insulin syringe, and the tumor cells are injected into the nude mouse tail vein without resistance from a direction parallel to the tail vein. During the injection process, the blood flow in the tail vein can be seen to be pushed away by the injection solution. The blood will return immediately after the injection is completed. The syringe needle is pulled out after pressing with an alcohol cotton ball.

[0096] Four weeks after injection, the metastasis and colonization of tumor cells were observed using an in vivo imaging device and bioluminescence principle. The specific operation was as follows: 200 μL of luciferase substrate D(-)-Luciferin (15 mg / mL) was injected intraperitoneally into nude mice 15 min before detection. After isoflurane inhalation anesthesia, the mice were placed in a small animal in vivo imaging system for fluorescence imaging detection, and images were acquired and saved.

[0097] Seven weeks after injection, mice were killed by cervical dislocation, lung tissues were collected and fixed in 4% paraformaldehyde fixative for 48 h, tissues were dehydrated, paraffin-embedded and sliced, and hematoxylin-eosin (HE) and PAN-CK staining were performed. After the tissue images were acquired by slice scanner, the formation of metastatic lesions was observed and the source of metastatic lesions was confirmed. All operations in animal experiments strictly followed the Guide for the Care and Use of Laboratory Animals and were approved by the Ethics Committee of Sun Yat-sen University.

[0098] (1) Paraffin embedding and sectioning: First, take out the tissue sample fixed in 4% paraformaldehyde for 48 hours, trim the tissue and put it into the embedding frame, and then put it in the tissue dehydrator for automatic dehydration. After taking out the tissue embedding frame from the dehydrator, put it into the wax pool of the embedding machine and soak it for 1-2 hours. After the wax around the tissue is completely melted, take out the embedding frame from the wax pool, select a suitable embedding mold according to the size of the tissue, drip the melted wax on the bottom of the embedding mold, and place the mold on an ice table. After the wax is slightly solidified, use tweezers to put the tissue in and press it to prevent bubbles. Then move the mold as a whole to the hot table and embed the embedding frame on top of the mold. Then drip wax from the top until the surface of the embedding frame is completely covered with wax liquid. Move the whole to the ice table and let it stand for 2 hours. Use a triangular scissors to remove the embedding frame from the mold.

[0099] Before slicing, place the wax block in a -20℃ refrigerator for precooling. When slicing, fix the wax block on the microtome. After moving to the appropriate position, trim the wax block to the section to be observed with a thickness of 20μm, and then switch to a thickness of 4μm for continuous slicing. Use tweezers and a brush to pick up the cut tissue and spread it flat in 40℃ water. Use tweezers to separate the desired tissue position in the water, use the marked front of the slide to pick up the tissue from underwater at a 45℃ tilt, shake off excess water, bake the slices at 60℃ for 2h, and then store them in a 4℃ refrigerator.

[0100] (2) Hematoxylin-eosin (HE) staining

[0101] HE staining was used to observe the effect of PLIN2 overexpression on lung metastasis of OSCC cells in nude mice. The specific experimental method is as follows: first, the paraffin sections were placed in a 60°C baking slice for 1 hour, and then dewaxed in an environmentally friendly transparent dewaxing solution for 2 times, 10 minutes each time, and then soaked in different concentrations (100%, 100%, 95%, 80%) of alcohol for 1 minute each, and then soaked in pure water for 1 minute. Secondly, the hematoxylin stain was added to the tissue sections to stain the cell nucleus, stained at room temperature for 5 minutes, rinsed with running water for 1 minute, and then differentiated with 1% hydrochloric acid alcohol for 5 seconds, and then rinsed with running water again for 10 minutes. Then, the eosin stain was added to the tissue sections to stain the cytoplasm, stained at room temperature for 2 minutes, and then directly soaked in different concentrations (80%, 95%, 100%, 100%) of alcohol for 1 minute each, and then dewaxed in an environmentally friendly transparent dewaxing solution for 2 times, 5 minutes each time. Finally, seal the slides with neutral gum and coverslips of appropriate size. After ensuring that no bubbles are generated, allow the slides to dry naturally at room temperature. Use a slide scanner to acquire and save images.

[0102] (3) Immunohistochemistry (IHC) staining

[0103] By using mouse anti-human cytokeratin IHC staining, we confirmed whether the lung tumor metastasis in the nude mouse tail vein metastasis model was an epithelial tumor. The specific experimental method is as follows:

[0104] (3.1) Baking and dewaxing: Baking the slices at 60°C for 1 h, then dewaxing in an environmentally friendly transparent dewaxing solution twice, each time for 10 min;

[0105] (3.2) Rehydration: Soak the sections in different concentrations of alcohol (100%, 100%, 95%, 80%, 75%) for 5 min each;

[0106] (3.3) Membrane disruption: Soak the sections in 0.1% Triton X-100 solution for 10 min, then wash with PBS three times, 5 min each time;

[0107] (3.4) Elimination of endogenous peroxidase: 3% hydrogen peroxide solution (solution A in the DAB kit) was added dropwise to the tissue surface, incubated in the dark at room temperature for 10 min, and then washed with PBS three times, 5 min each time;

[0108] (3.5) Antigen retrieval: Prepare fresh citrate retrieval solution (pH 6.0) or EDTA antigen retrieval solution (pH 9.0) according to the retrieval method recommended in the instructions for use of the primary antibody. Heat the solution in a microwave oven at 100% power for 10 min to bring it to a boiling state. Remove the sections from the PBS solution and quickly place them in the antigen retrieval solution. Heat the solution in a microwave oven at 40% power for 12 min. Remove the sections and allow them to cool naturally to room temperature before washing them three times with PBS for 5 min each time.

[0109] (3.6) Blocking: Gently shake off the PBS solution but do not dry the slides. Use a histochemical pen to draw a circle 1-2 mm along the edge of the tissue. Add ready-to-use goat serum on top of the tissue and incubate for 30 min to avoid nonspecific staining.

[0110] (3.7) Primary antibody incubation: Calculate the required volume of primary antibody based on the amount of tissue, dilute the primary antibody with antibody diluent, gently shake off the goat serum but do not dry the slices, and drop the primary antibody on top of the tissue (PAN-CK primary antibody is a ready-to-use working solution and does not need to be diluted); then place the slices in a humidified box and incubate overnight in a 4°C refrigerator;

[0111] (3.8) Secondary antibody incubation: Gently shake off the primary antibody serum but do not dry the slides, soak in 0.1% PBST solution twice, 5 min each time, and then soak in PBS solution for 5 min; then drop universal anti-mouse / rabbit HPR-secondary antibody on the tissue, incubate at room temperature for 30 min, soak in 0.1% PBST solution twice, 5 min each time, and then soak in PBS solution for 5 min;

[0112] (3.9) Color development: Prepare fresh DAB color development solution according to the instructions of the DAB kit. Add an appropriate amount of color development solution according to the size of the tissue and continue to observe under a microscope. When the positive area turns brown-yellow, rinse it in tap water to stop the color development, and then immerse the slices in pure water;

[0113] (3.10) Nuclear counterstaining: Add hematoxylin staining solution onto the tissue, stain for 10-30 seconds at room temperature, and rinse with running water for 10 minutes;

[0114] (3.11) Dehydration and transparency: The sections were immersed in different concentrations of alcohol (75%, 80%, 95%, 100%) for 5 min each, and then dewaxed in environmentally friendly transparent dewaxing solution twice, each time for 5 min;

[0115] (3.12) Sealing and image acquisition: Use neutral gum and a coverslip of appropriate size to seal the slides. After ensuring that no bubbles are generated, allow the slides to dry naturally at room temperature. Use a slide scanner to acquire and save images.

[0116] In order to verify the result of PLIN2 promoting OSCC metastasis in vivo, in this example, the HSC3 stable transgenic strain overexpressing PLIN2 was injected into the nude mice of the experimental group via the tail vein, during which the lung metastasis of tumor cells was observed by in vivo imaging ( Figure 7 A); 7 weeks after injection, the mice were killed, samples were collected and HE staining was performed. It was found that 7 mice in the experimental group (n=15) had tumor metastases in the lungs, while only 2 mice in the control group (n=15) had lung metastases. The corresponding PAN-CK staining showed that the tumor metastases in the lungs were of epithelial origin ( Figure 7 B); Statistical analysis found that there was a significant difference in the metastasis rate between the two groups ( Figure 7 C), indicating that PLIN2 overexpression promotes the metastasis of OSCC cells in vivo.

[0117] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.

Claims

1. A molecular marker associated with oral squamous cell carcinoma metastasis, characterized in that: The molecular markers include PLIN2.

2. The molecular marker according to claim 1, characterized in that The PLIN2 is highly expressed in patient samples of oral squamous cell carcinoma metastasis.

3. Use of a reagent for detecting the expression level of the molecular marker gene and / or protein according to any one of claims 1 to 2 in the preparation of a product for early diagnosis of oral squamous cell carcinoma metastasis or prognosis.

4. A kit for early diagnosis of oral squamous cell carcinoma metastasis or prognosis, characterized in that: The kit comprises a reagent for detecting the expression level of the molecular marker gene and / or protein according to any one of claims 1-2.

5. The kit according to claim 4, characterized in that The kit includes primers with nucleotide sequences as shown in SEQ ID NO.1 and SEQ ID NO.

2.

6. Application of PLIN2 as a target in screening or preparing drugs for early intervention of oral squamous cell carcinoma metastasis.

7. Use of a preparation that inhibits the expression level of PLIN2 gene and / or protein in the preparation of a drug for treating metastasis of oral squamous cell carcinoma.

8. The use according to claim 7, characterized in that The agent for inhibiting the expression level of PLIN2 gene and / or protein includes Si-RNA that targets and knocks down PLIN2.

9. The use according to claim 8, characterized in that The nucleotide sequence of the Si-RNA is shown as SEQ ID NO.3 or SEQ ID NO.

4.

10. A drug for treating oral squamous cell carcinoma metastasis, characterized in that: The medicine includes an agent that inhibits the expression level of PLIN2 gene and / or protein.